Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Insulet's peak revenue was $2.1B in 2024. The peak quarterly revenue was $597.5M in 2024(q4).
Insulet's revenue increased from $3.7m in 2006 to $2.1B currently. That's a 56,454.74% change in annual revenue.
| Fiscal year / year | Insulet revenue |
|---|---|
| 2009 | $66.0M |
| 2010 | $97.0M |
| 2011 | $152.3M |
| 2012 | $211.4M |
| 2013 | $247.1M |
| 2014 | $231.3M |
| 2015 | $263.9M |
| 2016 | $367.0M |
| 2017 | $463.8M |
| 2018 | $563.8M |
| 2019 | $738.2M |
| 2020 | $904.4M |
| 2021 | $1.1B |
| 2022 | $1.3B |
| 2023 | $1.7B |
| 2024 | $2.1B |
How accurately did Insulet's revenue projections match actual performance?
Insulet saw the greatest revenue growth in 2007, when revenue increased by 265.06%.
Insulet had the lowest revenue growth in 2014, when revenue changed by -6.38%.
| Year | Insulet growth |
|---|---|
| 2009 | 83%↑ |
| 2010 | 47%↑ |
| 2011 | 57%↑ |
| 2012 | 39%↑ |
| 2013 | 17%↑ |
| 2014 | -6%↓ |
| 2015 | 14%↑ |
| 2016 | 39%↑ |
| 2017 | 26%↑ |
| 2018 | 22%↑ |
| 2019 | 31%↑ |
| 2020 | 23%↑ |
| 2021 | 21%↑ |
| 2022 | 19%↑ |
| 2023 | 30%↑ |
| 2024 | 22%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $12.5M | $14.6M | $18.7M | $20.2M |
| 2010 | $20.8M | $22.9M | $25.5M | $27.8M |
| 2011 | $28.3M | $32.2M | $44.6M | $47.2M |
| 2012 | $47.8M | $51.0M | $54.8M | $57.8M |
| 2013 | $57.4M | $60.1M | $61.1M | $68.5M |
| 2014 | $69.2M | $72.0M | $75.0M | $15.2M |
| 2015 | $48.1M | $60.6M | $71.4M | $83.8M |
| 2016 | $81.2M | $87.3M | $94.9M | $103.6M |
| 2017 | $101.7M | $109.8M | $121.8M | $130.5M |
| 2018 | $123.6M | $124.3M | $151.1M | $164.9M |
| 2019 | $159.6M | $177.1M | $192.1M | $209.4M |
| 2020 | $198.0M | $226.3M | $234.0M | $246.1M |
| 2021 | $252.3M | $263.2M | $275.6M | $307.7M |
| 2022 | $295.4M | $299.4M | $340.8M | $369.7M |
| 2023 | $358.1M | $396.5M | $432.7M | $509.8M |
| 2024 | $441.7M | $488.5M | $543.9M | $597.5M |
Do you work at Insulet?
Is Insulet transparent about its revenue structure?
| Industry | Software & Services |
| Company Type | Public |
| Employees Number | 1,169 |
| Date Founded | 2000 |
| Headquarters | Acton, Massachusetts |
| Number of Locations | 11 |
| Revenue | $2.1B |
| Net Income | $4,600,000 |
| Gross Proft | $1.4B (2024) |
| PE Ratio | 11.66 |
| Tax Rate | -0.4% |
| Market Capitalization | $4.9B |
| Total Assets | $2,251,100,000 |
| Ticker | PODD |
Insulet received early financing of $50.0M on 2006-02-16.
| Series | Round size | Date |
|---|---|---|
| Series E | $50M | 02/2006 |
| Investors | Security type |
|---|---|
| Prism Venture Management | Series E |
| Federated Kaufmann Fund | Series E |
| Versant Ventures | Series E |
| Alta Partners | Series E |
| OrbiMed Advisors | Series E |
| Schroders | Series E |
| Pequot Capital | Series E |
Insulet's top competitor, BD, earned an annual revenue of $19.4B.
Insulet's smallest competitor is Calibra Medical with revenue of $1.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Calibra Medical | $46,026 | $1.5M | 13 | - |
| Tandem Diabetes Care | $62,371 | $940.2M | 1,500 | 3 |
| Ivenix | $45,715 | $9.9M | 49 | 1 |
| Bigfoot Biomedical | $101,236 | $25.0M | 113 | - |
| BD | $69,049 | $19.4B | 76,032 | 236 |
| Harbor Healthcare System | $42,397 | $47.0M | 500 | 235 |
| VNA Care | $49,488 | $5.1M | 30 | 38 |
| Ogden Clinic | $48,382 | $6.7M | 54 | 142 |
| LifeScan | $56,476 | $1.5B | 2,400 | 26 |
| rms | $50,140 | $340.0M | 700 | 49 |
Zippia gives an in-depth look into the details of Insulet, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Insulet. The employee data is based on information from people who have self-reported their past or current employments at Insulet. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Insulet. The data presented on this page does not represent the view of Insulet and its employees or that of Zippia.
Insulet may also be known as or be related to INSULET CORP, Insulet and Insulet Corporation.